The objective of the NEUTROSURGERY study is to describe the local and locoregional immuno-inflammatory activity in patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy compared to a control population of patients to be operated on in neurosurgery for another neurosurgical pathology.
Collegial indication given by a neurologist, a neuroreanimator and a neurosurgeon for HD in the context of a malignant sylvian AIC.
HD carried out in a context of acute cerebral haemorrhage
Pre-existing neurological disability: modified Rankin score > 2
Patient benefiting from a legal protection measure
None
The target population concerns patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy. Eligibility will be assessed as soon as the first results of the MRI or brain scan carried out as part of the thrombolysis alert by the interventional neurologist or neuroradiologist triggering the treatment, in front of a large ischaemic cerebral accident (\>145 ml).
Case-control
Prospective
Decompressive hemicraniectomy
Procedure/SurgeryDecompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
neurosurgical operation
Procedure/Surgeryneurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
neutrophil polynuclear cells levels
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
